Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Kymera Therapeutics, Inc.
KYMR
NASDAQ·Healthcare·Biotechnology·Mkt cap $9.4B
$112.64
▼ -1.37%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$36.65 - $130.05
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 156.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary targeted protein degradation platform enabling selective elimination of disease-causing proteins
- First-mover advantage in PROTAC and E3 ligase-based therapeutic modality with multiple clinical programs
- Ability to target previously undruggable proteins using the body's natural protein disposal mechanisms
- Diversified pipeline across high-value therapeutic areas with significant unmet medical needs
Bear Case
1 risk
- High volatility (beta 2.0). Larger-than-normal price swings expected.
Growth
Mild headwinds expected
Clinical trial progression and regulatory milestones for IRAK4, IRAKIMiD, STAT3, and MDM2 programs
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+33.7% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying KYMR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 8, 2026
APR 30, 2026
Reported EPS of -$0.71 vs -$0.89 consensus (+20.2% surprise). Revenue of $34.4M vs $8.3M expected (+315.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+20.2%
Next: May 8, 2026
Revenue trend · last 8Q
—
—
-85%
+115%
-55%
-26%
-61%
+55%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$25.6M
$3.7M
$7.4M
$22.1M
$11.5M
$2.8M
$2.9M
$34.4M
Margins · last 8Q
Gross
100.0%
Operating
—
Profit
-201.5%
Wall Street consensus
8 analysts · 88% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
88%
Hold
13%
Sell
0%
Median Price Target
$119.00
▲ +5.6% vs $112.64
Latest: B. Riley · Jun 29, 2026
3 analysts covering